サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1770162

急性骨髄性白血病（AML）治療薬の世界市場

Acute Myeloid Leukemia (AML) Therapeutics

出版日
ページ情報
英文 356 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
急性骨髄性白血病（AML）治療薬の世界市場
出版日: 2025年07月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 356 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

急性骨髄性白血病（AML）治療薬の世界市場は2030年までに17億米ドルに達する見込み

2024年に7億8,570万米ドルと推定される急性骨髄性白血病（AML）治療薬の世界市場は、分析期間2024-2030年にCAGR 13.3%で成長し、2030年には17億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるシタラビンは、CAGR 15.3％を記録し、分析期間終了時には5億9,270万米ドルに達すると予測されています。アントラサイクリン系薬剤セグメントの成長率は、分析期間中CAGR 14.3％と推定されます。

米国市場は2億8,010万米ドルと推定、中国はCAGR 15.0％で成長すると予測

米国の急性骨髄性白血病（AML）治療薬市場は2024年に2億8,010万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億5,100万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは15.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.0％と12.0％と予測されています。欧州では、ドイツがCAGR 12.8%で成長すると予測されています。

世界の急性骨髄性白血病（AML）治療薬市場- 主要動向と促進要因まとめ

急性骨髄性白血病（AML）は、骨髄に発生し、急速に進行して血液や身体の他の部分に影響を及ぼすがんの一種です。異常な白血球が急速に増殖し、正常な血液細胞の産生を阻害するのが特徴です。AMLは高齢者で最も多く診断されますが、どの年齢でも発症する可能性があります。AMLの治療には、化学療法、標的療法、場合によっては幹細胞移植が併用されます。化学療法の種類には以下のようなものがあります。シタラビン、アントラサイクリン系薬剤、チロシンキナーゼ阻害剤、アルキル化剤、ホルモン療法、代謝拮抗剤などがあります。長年にわたり、AMLの遺伝的・分子的基盤の理解における進歩は、より効果的で個別化された治療法の開発につながり、患者の転帰と生存率を改善してきました。

AML治療における最近の進歩は、標的療法と免疫療法に焦点が当てられており、これらは健康な細胞へのダメージを最小限に抑えながら、がん細胞を特異的に標的とすることを目的としています。FLT3阻害剤やIDH阻害剤などの標的療法は、AMLに関連する特定の遺伝子変異の治療に有望です。モノクローナル抗体や免疫チェックポイント阻害剤を含む免疫療法は、白血病細胞に対する身体の免疫反応を増強する可能性について研究されています。これらの新規治療法の開発は、ゲノム・プロファイリングと分子診断学の進歩により、治療標的をより正確に特定できるようになったことで促進されています。臨床試験や調査研究は、AML患者の予後をさらに改善するための新たな治療戦略や併用療法を探求し続けています。

ゲノム研究の進展、AMLの有病率の増加、新規標的療法の開発など、いくつかの要因がAML市場の成長を牽引しています。AMLの遺伝学的・分子生物学的背景に対する理解の深まりは、個別化治療アプローチの開発に道を開いた。特に高齢化社会におけるAMLの罹患率の上昇により、効果的かつ革新的な治療法に対する需要が高まっています。診断と薬剤開発における技術の進歩は、新たな標的療法と免疫療法の導入につながり、AML患者の生存率とQOLの改善に希望をもたらしています。さらに、政府によるがん研究への資金援助や支援、製薬企業による最先端治療開発への関与も、市場の成長に寄与しています。こうした動向が続く中、AML治療薬市場は、より効果的で個別化された治療オプションの必要性によって拡大すると予想されます。

セグメント

化学療法タイプ（シタラビン、アントラサイクリン系薬剤、チロシンキナーゼ阻害剤、アルキル化剤、ホルモン療法、代謝拮抗剤、その他の化学療法タイプ）

調査対象企業の例

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AbbVie, Inc.
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Actinium Pharmaceuticals, Inc.
  • Aptose Biosciences, Inc.
  • Aprea Therapeutics
  • Astex Pharmaceuticals, Inc.
  • AB Science SA
  • Aptevo Therapeutics
  • Ascentage Pharma
  • arGEN-X
  • Accent Therapeutics
  • Arcellx
  • Amphivena Therapeutics

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • 中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6847

Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach US$1.7 Billion by 2030

The global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$785.7 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2024-2030. Cytarabine, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$592.7 Million by the end of the analysis period. Growth in the Anthracycline Drugs segment is estimated at 14.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$280.1 Million While China is Forecast to Grow at 15.0% CAGR

The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$280.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$151.0 Million by the year 2030 trailing a CAGR of 15.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.0% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.8% CAGR.

Global Acute Myeloid Leukemia (AML) Therapeutics Market - Key Trends & Drivers Summarized

Acute Myeloid Leukemia (AML) is a type of cancer that originates in the bone marrow and rapidly progresses to affect the blood and other parts of the body. It is characterized by the rapid growth of abnormal white blood cells that interfere with normal blood cell production. AML is most commonly diagnosed in older adults, but it can occur at any age. The treatment of AML involves a combination of chemotherapy, targeted therapy, and in some cases, stem cell transplantation. Some of the chemotherapy types are: Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites, among other types. Over the years, advancements in understanding the genetic and molecular basis of AML have led to the development of more effective and personalized treatment options, improving patient outcomes and survival rates.

Recent advancements in AML therapeutics have focused on targeted therapies and immunotherapies, which aim to specifically target cancer cells while minimizing damage to healthy cells. Targeted therapies, such as FLT3 inhibitors and IDH inhibitors, have shown promise in treating specific genetic mutations associated with AML. Immunotherapies, including monoclonal antibodies and immune checkpoint inhibitors, are being investigated for their potential to enhance the body's immune response against leukemia cells. The development of these novel therapies has been facilitated by advancements in genomic profiling and molecular diagnostics, allowing for more precise identification of therapeutic targets. Clinical trials and research efforts continue to explore new treatment strategies and combinations to further improve outcomes for AML patients.

The growth in the Acute Myeloid Leukemia (AML) therapeutics market is driven by several factors, including advancements in genomic research, increasing prevalence of AML, and the development of novel targeted therapies. The growing understanding of the genetic and molecular landscape of AML has paved the way for the development of personalized treatment approaches. The rising incidence of AML, particularly among the aging population, has increased the demand for effective and innovative therapies. Technological advancements in diagnostics and drug development have led to the introduction of new targeted therapies and immunotherapies, offering hope for improved survival rates and quality of life for AML patients. Additionally, government funding and support for cancer research, along with the involvement of pharmaceutical companies in developing cutting-edge treatments, are contributing to the market's growth. As these trends continue, the AML therapeutics market is expected to expand, driven by the need for more effective and personalized treatment options.

SCOPE OF STUDY:

The report analyzes the Acute Myeloid Leukemia (AML) Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Chemotherapy Type (Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites, Other Chemotherapy Types)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 112 Featured) -

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AbbVie, Inc.
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Actinium Pharmaceuticals, Inc.
  • Aptose Biosciences, Inc.
  • Aprea Therapeutics
  • Astex Pharmaceuticals, Inc.
  • AB Science SA
  • Aptevo Therapeutics
  • Ascentage Pharma
  • arGEN-X
  • Accent Therapeutics
  • Arcellx
  • Amphivena Therapeutics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Competition
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Acute Myeloid Leukemia (AML) Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Acute Myeloid Leukemia (AML) Therapeutics Competitor Market Share Scenario Worldwide (in %): 2022E
  • LEUKEMIA - A DISEASE OF THE BONE MARROW
    • A Prelude to Acute Myeloid Leukemia (AML)
    • Acute Myeloid Leukemia: Epidemiology
    • Acute Myeloid Leukemia (AML) Types
    • The FAB Classification of AML
    • WHO AML Classification
    • Etiology of AML
    • AML Symptoms
  • GLOBAL MARKET OUTLOOK AND PROSPECTS
    • Acute Myeloid Leukemia (AML) Therapeutics Market Primed for Massive Growth with Rising Patient Count & Promising Research Efforts
    • Drug Development Efforts Set Pace for Global Market
    • New Therapies Introduced in the Landscape
  • RECENT LAUNCHES IN THE AML MARKET
    • North America Maintains Leadership Position in Global Market
    • Chemotherapy: The Standard Mode of Treatment for AML Over the Years
    • Emerging Drug Therapies/Targeted Therapies for Acute Myeloid Leukemia to Drive the Market
    • FLT3 Inhibitors & Cytarabine: Bright Segments of Acute Myeloid Leukemia Therapeutics Market
    • Global FLT3 Inhibitors Market: Annual Sales in US$ Million for Years 2020 through 2027
    • EXISTING & POTENTIAL TREATMENT/THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA
    • Chemotherapy
    • AML Treatment
    • Stem Cell Transplant for Acute Myeloid Leukemia (AML)
    • Targeted Therapies Drive the Future of AML Market
    • ISOCITRATE DEHYDROGENASES (IDH)
    • BCL-2 Inhibitor
    • FLT3
    • Hedgehog (Hh)
    • Immunotherapy-Oriented Treatments
    • Neurotransmitter Receptors
    • Epigenetic Modulators
    • Organelle-Directed Strategies
    • New Formulations Using Existing Options
    • Antibody-Drug Conjugate Therapy for Acute Leukemia
    • Competitive Environment of AML Market
  • RECENT MARKET ACTIVITY
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Incidence and Prevalence Drive Market Growth
    • Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics
    • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • Advancements in Pharmacology & Molecular Biology to Promote AML Drug Development
    • Recent Drug Approvals
    • Rising Investments in AML Therapeutics R&D Augurs Well
    • Changing Face of Combination Therapies Improve Outcomes for treated Secondary AML
    • University of Texas' Combination Therapy Study Shines Light at the end of Tunnel for Acute Myeloid Leukemia
    • Need for Better Treatments Entrenches Proteomics at Center of Acute Myeloid Leukemia Therapeutics R&D
    • Antibody-Oriented Protein Microarrays
    • AML - A Medical Challenge with High Relapse Rate
    • Therapeutic Landscape for Refractory/Relapsed Acute Myeloid Leukemia
    • Advances Related to FLT3 Inhibitors
    • Gilteritinib to Set New Therapeutic Paradigm for Acute Myeloid Leukemia
    • Novel Combination Therapies for Relapsed or Refractory AML
    • Novel Therapies for Treatment of Pediatric Relapsed AML
    • Immunotherapy Research for AML
    • Monoclonal Antibody (Mylotarg) - A Promising Drug
    • Chemotherapy Complications to Hinder the AML Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Cytarabine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Anthracycline Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Anti-Metabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Chemotherapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Acute Myeloid Leukemia (AML) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • CHINA
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Europe 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: France 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 47: Germany Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Germany 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Italy 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 53: UK Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: UK 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 56: Spain Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Spain Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Spain 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 59: Russia Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Russia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Russia 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Rest of Europe 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Asia-Pacific 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Asia-Pacific 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 71: Australia Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Australia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Australia 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • INDIA
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: India 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 77: South Korea Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: South Korea Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: South Korea 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Rest of Asia-Pacific 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Latin America 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Middle East 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 89: Africa Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Africa Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Africa 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2015, 2025 & 2030

IV. COMPETITION